Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019
29 avr. 2019 07h00 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, April 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
18 mars 2019 06h50 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
13 mars 2019 17h15 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
06 mars 2019 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
05 févr. 2019 07h00 HE
|
Protalix BioTherapeutics, Inc.
~Pharmacokinetic data from patients treated in the study show that infusion of pegunigalsidase alfa every 4 weeks results in the presence of continuous active enzyme throughout the entire infusion...
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
28 janv. 2019 07h00 HE
|
Protalix BioTherapeutics, Inc.
~Oral presentation to include pharmacokinetic and anti-drug antibody data for first 15 patients enrolled~ CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,...
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
17 déc. 2018 07h00 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
07 nov. 2018 07h00 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018
29 oct. 2018 07h00 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
05 oct. 2018 07h00 HE
|
Protalix BioTherapeutics, Inc.
~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A deterioration trend in patients’...